Squarepoint Ops LLC Has $3.48 Million Stock Position in STERIS plc (NYSE:STE)
Squarepoint Ops LLC increased its stake in STERIS plc (NYSE:STE) by 537.4% in Q4, owning 16,923 shares valued at $3.48 million. Other investors also modified their holdings. STERIS reported a quarterly EPS of $2.74, exceeding estimates, with a revenue of $1.48 billion. The company announced a quarterly dividend of $0.57 per share, with a yield of 0.94%. Analysts have given STERIS a "Moderate Buy" rating, with an average price target of $264.00.
Squarepoint Ops LLC lifted its stake in shares of STERIS plc (NYSE:STE - Free Report) by 537.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,923 shares of the medical equipment provider's stock after purchasing an additional 14,268 shares during the quarter. Squarepoint Ops LLC's holdings in STERIS were worth $3,479,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of STE. Avalon Trust Co acquired a new stake in shares of STERIS during the 4th quarter worth $30,000. Human Investing LLC acquired a new stake in shares of STERIS during the 4th quarter worth $31,000. Anfield Capital Management LLC grew its holdings in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares in the last quarter. Manchester Capital Management LLC grew its holdings in shares of STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 137 shares in the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in shares of STERIS by 66.7% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock worth $45,000 after buying an additional 88 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.
STERIS Price Performance
STERIS stock opened at $243.21 on Tuesday. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $23.90 billion, a PE ratio of 51.64 and a beta of 0.96. STERIS plc has a 12 month low of $200.98 and a 12 month high of $252.79. The stock has a 50-day moving average price of $226.61 and a two-hundred day moving average price of $220.26.
STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, beating the consensus estimate of $2.59 by $0.15. The firm had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The business's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $2.58 earnings per share. Analysts expect that STERIS plc will post 9.08 EPS for the current year.
STERIS Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.94%. STERIS's dividend payout ratio (DPR) is 36.77%.
Analyst Ratings Changes
STE has been the subject of several recent analyst reports. Morgan Stanley upped their price objective on STERIS from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research report on Monday, May 19th. JMP Securities upped their price objective on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday, May 16th. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. Piper Sandler upped their price objective on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, Stephens restated an "overweight" rating and set a $250.00 price objective on shares of STERIS in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, STERIS has an average rating of "Moderate Buy" and an average price target of $264.00.
Check Out Our Latest Analysis on STERIS
STERIS Profile
(Free Report)STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- How to trade using analyst ratings
- Workday Stock Price Implosion: An Automatic Buy for AI Investors
- How to Profit From Value Investing
- MercadoLibre Is Soaring—Should You Wait for a Better Entry?
- 3 Warren Buffett Stocks to Buy Now
- Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in STERIS Right Now?
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
